Key Insights

Highlights

Success Rate

85% trial completion

Published Results

148 trials with published results (16%)

Research Maturity

483 completed trials (52% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

9.1%

85 terminated out of 935 trials

Success Rate

85.0%

-1.5% vs benchmark

Late-Stage Pipeline

13%

117 trials in Phase 3/4

Results Transparency

31%

148 of 483 completed with results

Key Signals

148 with results85% success85 terminated

Data Visualizations

Phase Distribution

705Total
Not Applicable (248)
Early P 1 (10)
P 1 (123)
P 2 (207)
P 3 (85)
P 4 (32)

Trial Status

Completed483
Unknown143
Recruiting123
Terminated85
Active Not Recruiting54
Withdrawn24

Trial Success Rate

85.0%

Benchmark: 86.5%

Based on 483 completed trials

Clinical Trials (935)

Showing 20 of 20 trials
NCT07467824Not ApplicableRecruiting

Impact of Prehabilitation and Comprehensive Follow-up in Women With Breast Cancer

NCT07060807Phase 3RecruitingPrimary

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

NCT01251900CompletedPrimary

BRCA Mutations in Latinas

NCT00475761CompletedPrimary

Breast Mammogram and Tissue Study

NCT05509790Phase 1Active Not RecruitingPrimary

A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer

NCT04767594Active Not RecruitingPrimary

First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.

NCT05263362Completed

An Integrated Optimization of Surgery and Radiotherapy Techniques to Improve Cosmetic Outcome and Quality of Life in Breast Conserving Therapy for Breast Cancer Patients (STARLINGS Study)

NCT06966700Phase 3RecruitingPrimary

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

NCT07214532Not ApplicableRecruitingPrimary

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

NCT04544189Phase 2Active Not RecruitingPrimary

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer

NCT05514054Phase 3Active Not RecruitingPrimary

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

NCT06312176Phase 3RecruitingPrimary

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

NCT06926868Phase 2RecruitingPrimary

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

NCT06830720RecruitingPrimary

A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence

NCT07505797Recruiting

ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)

NCT07495358Not ApplicableNot Yet RecruitingPrimary

Development and Usability Evaluation of a Knowledge Graph-Based Symptom Management System for Patients With Breast Cancer Undergoing Chemotherapy

NCT04918082Active Not RecruitingPrimary

Assessment of Quality of Life and Treatment Times for Patients With Invasive Type Breast Cancer in Martinique

NCT07500038Not ApplicableCompletedPrimary

Evidence-Based Practice for the Management of Musculoskeletal Symptoms in Breast Cancer Patients Undergoing Endocrine Therapy: A Multicultural Perspective

NCT07500428RecruitingPrimary

Construction of a Benchmark for Breast Ultrasound AI Interpretation and Performance Evaluation of Multimodal AI Models

NCT07287098Phase 2Not Yet RecruitingPrimary

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

Scroll to load more

Research Network

Activity Timeline